Aplagon Oy
🇫🇮Finland
- Country
- 🇫🇮Finland
- Ownership
- Holding
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.aplagon.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Early Phase 1:1
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (50.0%)Phase 1
1 (50.0%)Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)
Early Phase 1
Recruiting
- Conditions
- Peripheral Arterial Occlusive DiseaseCritical Limb Ischemia
- Interventions
- Radiation: PET/CT scan
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Aplagon Oy
- Target Recruit Count
- 10
- Registration Number
- NCT06204237
- Locations
- 🇳🇱
The University Medical Center Groningen, Groningen, Netherlands
News
No news found